Mark M. Davis

发表

Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).

T. Merigan, J. Schapiro, C. Gray, 1999, Journal of immunology.

Transfer of putative complementarity-determining region loops of T cell receptor V domains confers toxin reactivity but not peptide/MHC specificity.

E. Rock, M. Davis, B. Fazekas de St. Groth, 1993, Journal of Immunology.

A human T cell-specific molecule is a member of a new gene family.

T. Schall, J. Jongstra, M. Davis, 1988, Journal of immunology.

Requirement of a second signal from antigen presenting cells in the clonal deletion of immature T cells.

M. Davis, O. Mazda, Y. Katsura, 1994, International immunology.

Antigen-specific, I-A-restricted suppressor hybridomas with spontaneous cytolytic activity. Functional properties and lack of rearrangement of the T cell receptor beta chain genes

M. Davis, G. Hämmerling, K. Yamamoto, 1985, The Journal of experimental medicine.

A model for T cell receptor and MHC/peptide interaction.

P. Bjorkman, M. Davis, M M Davis, 1989, Advances in experimental medicine and biology.

Molecular components of T-cell recognition.

M. Davis, J. Jorgensen, P. Reay, 1992, Annual review of immunology.

Evidence for a conformational change in a class II major histocompatibility complex molecule occurring in the same pH range where antigen binding is enhanced

N. Allbritton, M. Davis, D. Wettstein, 1996, The Journal of experimental medicine.

Expression of T cell antigen receptor heterodimers in a lipid-linked form.

M. Davis, J. Elliott, C. Sagerström, 1990, Science.

Low affinity interaction of peptide-MHC complexes with T cell receptors.

M. Davis, B. Fazekas de St. Groth, P. Reay, 1991, Science.

The XLR gene product defines a novel set of proteins stabilized in the nucleus by zinc ions

M. Davis, H. Garchon, Mark M. Davis, 1989, The Journal of cell biology.

Expression of a class II major histocompatibility complex (MHC) heterodimer in a lipid-linked form with enhanced peptide/soluble MHC complex formation at low pH

M. Davis, D. Wettstein, P. Reay, 1991, The Journal of experimental medicine.

T cell receptor interaction with peptide/major histocompatibility complex (MHC) and superantigen/MHC ligands is dominated by antigen

Y. Chien, E. Rock, M. Davis, 1993, The Journal of experimental medicine.

A peptide antigen antagonist prevents the differentiation of T cell receptor transgenic thymocytes.

L. Spain, M. Davis, J. Jorgensen, 1994, Journal of immunology.